文献速递肝病消化道肿瘤与早癌

Meta分析:Fontan姑息术后患者肝硬化与肝细胞癌的发生率

Meta-analysis: Incidence of cirrhosis and hepatocellular carcinoma in patients with Fontan palliation.
PubMed 文献 · Aliment Pharmacol Ther · 2024-03-18

该系统综述与Meta分析检索7个数据库共1158条记录,最终纳入23项研究,评估Fontan姑息术后患者肝硬化与肝细胞癌的发生率并按术后时间分层。肝硬化发生率为每100患者年0.97(95%CI 0.57-1.63),肝细胞癌为每100患者年0.12(95%CI 0.07-0.21),术后≥20年两者发生率及累积发生率均升高,仅约70%的肝细胞癌患者(20/28)存在 underlying cirrhosis。作者认为需进一步研究识别高危患者以优化监测。

要点

  • Fontan术后肝硬化发生率为每100患者年0.97(95%CI 0.57-1.63)
  • Fontan术后肝细胞癌发生率为每100患者年0.12(95%CI 0.07-0.21)
  • 术后≥20年肝硬化与肝细胞癌的发生率及累积发生率均升高

核心结论

  • Fontan术后肝硬化与肝细胞癌的发生率随时间增加,尤其是术后≥20年。
  • 仅约70%的肝细胞癌患者(20/28)存在 underlying cirrhosis。
  • 需要开展研究进一步识别高危患者,以优化对这类高致残疾病的监测。

研究设计与样本

  • 系统综述与Meta分析,检索7个数据库共1158条记录。
  • 纳入报告Fontan患者肝硬化及肝细胞癌例数与Fontan术后时间的研究。
  • 肝硬化队列仅纳入全部患者均接受肝活检的研究;共纳入23项研究,肝硬化队列12项、肝细胞癌队列13项,其中2项同时纳入两个队列。

主要发现

  • 肝硬化发生率为每100患者年0.97(95%CI 0.57-1.63)。
  • Fontan术后≥20年肝硬化发生率为每100患者年1.61(95%CI 1.24-2.08),累积发生率为32.2%(95%CI 25.8%-39.4%)。
  • 肝细胞癌发生率为每100患者年0.12(95%CI 0.07-0.21)。
  • Fontan术后≥20年肝细胞癌发生率为每100患者年0.20(95%CI 0.12-0.35),累积发生率为3.9%(95%CI 2.2%-6.8%)。
  • 仅约70%的肝细胞癌患者(20/28)存在 underlying cirrhosis。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 作者指出需要开展研究进一步识别高危患者,以优化对这类高致残疾病的监测。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND AIMS: The Fontan palliation is the final stage of surgery for many children born with univentricular physiology. Almost all Fontan patients develop liver fibrosis which may eventually lead to cirrhosis and hepatocellular carcinoma (HCC). These are important causes of morbidity and mortality in these patients. We performed a systematic review and meta-analysis to assess the incidence of cirrhosis and HCC in Fontan patients and stratify it based on time since surgery. METHODS: A literature search of seven databases identified 1158 records. Studies reporting the number of cirrhosis and HCC cases in Fontan patients and time since Fontan surgery were included. In the cirrhosis cohort, we included only those studies where all patients underwent liver biopsy. RESULTS: A total of 23 studies were included: 12 and 13 studies in the cirrhosis and HCC cohorts, respectively, with two studies included in both cohorts. The incidence of cirrhosis was 0.97 per 100 patient-years (95% CI 0.57-1.63), with the incidence and cumulative incidence ≥20 years post Fontan surgery being 1.61 per 100 patient-years (95% CI 1.24-2.08) and 32.2% (95% CI 25.8%-39.4%), respectively. The incidence of HCC was 0.12 per 100 patient-years (95% CI 0.07-0.21), with the incidence and cumulative incidence ≥20 years post Fontan surgery being 0.20 per 100 patient-years (95% CI 0.12-0.35) and 3.9% (95% CI 2.2%-6.8%), respectively. Only about 70% of patients with HCC (20/28) had underlying cirrhosis. CONCLUSION: The incidence of cirrhosis and HCC increases over time, especially at ≥20 years post Fontan surgery. Studies are needed to further identify at-risk patients in order to streamline surveillance for these highly morbid conditions.

来源:Aliment Pharmacol Ther,查看原文。版权归原作者所有。

引用

  1. Hitawala AA, Gopalakrishna H, Mironova M, et al. Meta-analysis: Incidence of cirrhosis and hepatocellular carcinoma in patients with Fontan palliation. Aliment Pharmacol Ther. 2024. PMID: 38497159. doi:10.1111/apt.17952

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。